Search

everythinglearnresearchcommunity

for

Search:↓

Few dermatology programs mention gender-affirming care, highlighting a need for better training and visibility.

High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.

Transgender women have similar fitness to cisgender women, while transgender men have higher fat and lower strength than cisgender men; hormone therapy affects body composition and strength.

Facial aesthetic procedures improve quality of life for transgender individuals.

Oral estradiol works for many transgender women but needs personalized dosing and monitoring.

Sublingual minoxidil safely increases hair growth in transgender people on testosterone therapy.

Topical minoxidil helps transgender individuals assigned female at birth grow more facial hair.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

The transgender community in India has specific skin care needs and struggles to access dermatological services due to discrimination and financial issues.

Facial hair is crucial for gender affirmation, but many face financial barriers to achieving desired results.

Social rejection can harm long-term mental health in transgender individuals.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Feminizing hormone therapy increases hair counts and improves hair-related quality of life, while masculinizing therapy may reduce large terminal hairs.

Facial hair is crucial for transgender men's gender identity and transition.

Facial contouring is crucial for the satisfaction and well-being of Chinese transgender females.

Athletic trainers should understand and support the medical needs of transgender and gender-diverse patients.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Male pattern baldness may indicate arterial stiffness in transgender men on long-term testosterone therapy.

Healthcare providers need better education and resources to give competent and sensitive care to transgender patients.

Many LGBTQ individuals in Lahore face skin issues, with androgenic alopecia, dry skin, and scabies being common, highlighting the need for better healthcare access and provider training.

Testosterone treatment effectively causes male physical development in transgender male adolescents but may lead to side effects like acne, higher BMI and blood pressure, lower good cholesterol, and decreased bone density.

Topical 3% minoxidil effectively and safely enhances facial hair in transgender men.

Gender-affirming care greatly improves mental health for transgender and non-binary individuals.

The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.

Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.

Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.

The conclusion is that recognizing the difference between gender identity and biological sex is crucial in dermatology to improve patient care and research accuracy.

Gender affects hair and scalp characteristics, with differences in hormone responses, graying patterns, and trace metals.